About: Increased plasma heparanase activity in COVID-19 patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Increased plasma heparanase activity in COVID-19 patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Increased plasma heparanase activity in COVID-19 patients
Creator	Kox, Matthijs Joosten, Leo Netea, Mihai Peter, Van De Veerdonk, Frank De Mast, Quirijn Buijsers, Baranca De Graaf, Mark Duivenvoorden, Raphaël Jonkman, Inge Rother, Nils Yanginlar, Cansu Janssen, Nico De Nooijer, Aline Grondman, Inge Luuk, Maciej-Hulme, Nijenhuis, Tom Pickkers, Van Der Vlag,
Source	MedRxiv
abstract	Background: Several reports suggest endothelial dysfunction and loss of endothelial barrier function in COVID-19. It is well established that the endothelial glycocalyx-degrading enzyme heparanase (HPSE) contributes to vascular leakage and inflammation. Low molecular weight heparins (LMWH) serve as an inhibitor of heparanase. We hypothesize that heparanase contributes to the pathogenesis of COVID-19, and that HPSE may be inhibited by the use of LMWH. Methods: Heparanase activity and heparan sulfate levels were measured in plasma of healthy controls (n=10) and COVID-19 patients (n=48). Findings: Heparanase activity and heparan sulfate levels were significantly elevated in plasma of COVID-19 patients. There was an association between heparanase activity and disease severity including the need for intensive care and mechanical ventilation, lactate dehydrogenase levels and creatinine levels. Use of prophylactic low molecular weight heparin in non-ICU patients was associated with a reduced HPSE activity. Interpretation: Prophylactic doses of low molecular weight heparin reduces heparanase activity in COVID-19. In addition to HPSE inhibition, low molecular weight heparin contributes to anti-coagulation and may exert anti-inflammatory effects. Since there is no other clinically applied heparanase inhibitor currently available, treatment of COVID-19 patients with low molecular weight heparins should be explored. Funding: This study was financially supported by the Radboudumc PhD fellow program, consortium grant LSHM16058-SGF (GLYCOTREAT; a collaborative project financed by the PPP allowance made available by Top Sector Life Sciences & Health to the Dutch Kidney Foundation to stimulate public-private partnerships), ERC Advanced grant (#833247) and a Spinoza Grant of the Netherlands Organization for Scientific Research.
has issue date	2020-06-15(xsd:dateTime)
bibo:doi	10.1101/2020.06.12.20129304
has license	medrxiv
sha1sum (hex)	8b50747d7ff81687d722dc9d1aef5795c395ba2d
schema:url	https://doi.org/10.1101/2020.06.12.20129304
resource representing a document's title	Increased plasma heparanase activity in COVID-19 patients
resource representing a document's body	covid:8b50747d7ff81687d722dc9d1aef5795c395ba2d#body_text
is schema:about of	named entity 'mechanical ventilation' named entity 'hypothesize' named entity 'controls' named entity 'There' named entity 'function' named entity 'COVID-19' named entity 'elevated' named entity 'heparanase' named entity 'activity' named entity 'heparanase' named entity 'COVID-19' named entity 'plasma' named entity 'heparan sulfate' named entity 'creatinine levels' named entity 'LMWH' named entity 'heparin' named entity 'prophylactic' named entity 'ICU' named entity 'HPSE' named entity 'mechanical ventilation' named entity 'COVID-19' named entity 'heparan sulfate' named entity 'LMWH' named entity 'Autopsy studies' named entity 'COVID' named entity 'recombinant' named entity 'peer review' named entity 'medRxiv' named entity 'COVID-19 disease' named entity 'COVID-19' named entity 'peer review' named entity 'doi' named entity 'ICU' named entity 'preprint' named entity 'peer review' named entity 'endothelial' named entity 'peer review' named entity 'IgM' named entity 'COVID' named entity 'lactate dehydrogenase' named entity 'preprint' named entity 'SARS-CoV-2' named entity 'medRxiv' named entity 'preprint' named entity 'renal disease' named entity 'medRxiv' named entity 'preprint' named entity 'preprint' named entity 'HPSE' named entity 'HPSE' named entity 'preprint' named entity 'antibody' named entity 'ICU' named entity 'preprint' named entity 'EDTA' named entity 'glycocalyx' named entity 'HPSE' named entity 'ICU' named entity 'Pfizer' named entity 'peer review' named entity 'ARDS' named entity 'HPSE' named entity 'heparanase' named entity 'plasma' named entity 'peer review' named entity 'creatinine'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software